Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.61 |
| ▸ | CTSS | P25774 | 6/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929938 | 1.00 | CTSK (0.61) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL8523201 | 1.00 | CTSK (0.61) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL7094 | 0.92 | ATM (0.62) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL1094506 | 0.92 | ATM (0.62) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL390555 | 0.92 | ATM (0.62) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL16945132 | 0.89 | CTSS (0.60) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL18995190 | 0.88 | CTSK (0.54) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL14274169 | 0.88 | PPARG (0.58) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL1912623 | 0.87 | CTSL (0.50) | CTSKCTSSCTSBCTSLACE | |
| SCHEMBL30867 | 0.85 | CTSS (0.59) | CTSKCTSSATMCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| CN-112661671-B | Preparation method of Sacubitril intermediate | 江苏阿尔法药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-112661671-A | Preparation method of Sacubitril intermediate | 江苏阿尔法药业有限公司 | 2021-04-16 | — | — | CN | disclosed |
| US-10479753-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2019-11-19 | — | — | US | disclosed |
| US-20170114006-A1 | SUBSTITUTED BIARYL ALKYL AMIDES | BIOTHERYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9546131-B2 | Substituted biaryl alkyl amides | BIOTHERYX, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-2121578-B1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2121578-B1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-9206116-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-2121578-A2 | NEW PROCESS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | CTSK 2667/4885CTSS 950/4885ATM 4839/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | CTSK 2667/4885CTSS 950/4885ATM 4839/4885 |
| US-20170114006-A1 | SUBSTITUTED BIARYL ALKYL AMIDES | AADAC, NAT1, GLS2 | CTSK 1842/4885CTSS 879/4885ATM 2724/4885 |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | MME, REN, BCAT2 | CTSK 2982/4885CTSS 1291/4885ATM 4871/4885 |
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | DPP4, ACE, DPP8 | CTSK 146/4885CTSS 378/4885ATM 3110/4885 |
| US-10479753-B2 | Sacubitril intermediate and preparation method thereof | ACE, DPP4, SI | CTSK 225/4885CTSS 509/4885ATM 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.